Table 1.
Population Estimates for Spain Considered in the Study
| Calculation of … | Item | Mean Value (Minimum-Maximum) | References |
|---|---|---|---|
| Prevalence of knee osteoarthritis (age ≥ 40 years) | – | 13.9% (12.7–15.1%) | Seoane, 201830 |
| Population over 40 (± 1%) | 2020 2021 2022 |
27,594,179 (27,318,237–27,870,120) 27,301,059 (27,028,048–27,574,069) 26,969,439 (26,699,744–27,239,133) |
INE, 201931 INE, 201931 INE, 201931 |
| Estimated number of patients with gonarthrosis | 2020 2021 2022 |
3,835,591 (3,469,416–4,208,388) 3,794,847 (3,432,562–4,163,684) 3,748,752 (3,390,868–4,113,109) |
Calculation 1 Calculation 1 Calculation 1 |
| % of patients with osteoarthritis receiving drug therapy | – | 93.99% (93.86–94.11%) | Wilson, 201532 |
| % of patients with osteoarthritis treated with NSAIDs/COXIBs | Acc. to the MPR* | 14.40% | Wilson, 201532 |
| % of patients with osteoarthritis treated with CS | Acc. to the MPR* | 21.2% | Wilson, 201532 |
| No. of patients with knee osteoarthritis treated with NSAIDs/COXIBs (MPR ≥ 50%)* | 2020 2021 2022 |
519,130 (422,029–627,345) 513,616 (417,546–620,681) 507,377 (412,474–613,142) |
Calculation 2 Calculation 2 Calculation 2 |
| No. of Droglican® units foreseen, based on annual sales up to July 2019 (± 10%)** | 2020 2021 2022 |
392,491 (353,242–431.740) 400,341 (360,307–440,375) 408,348 (367,513–449,182) |
Reig Jofre, 2019 |
| No. of units of Condrosan®/Condrosulf®/CS Kern foreseen, based on annual sales up to July 2019 (± 10%)** | 2020 2021 2022 |
2,993,624 (2,694,262–3,292,986) 3,053,496 (2,748,147–3,358,846) 3,114,566 (2,803,110–3,426,023) |
Reig Jofre, 2019 |
| Estimated number of patients treated with Droglican | 2020 2021 2022 |
6934 (6241–7627) 7073 (6365–7780) 7214 (6493–7936) |
Calculation 3 Calculation 3 Calculation 3 |
| Estimated number of patients treated with Condrosan®/Condrosulf®/CS Kern | 2020 2021 2022 |
105,775 (95,197–116,352) 107,890 (97,101–118,679) 110,048 (99,043–121,053) |
Calculation 3 Calculation 3 Calculation 3 |
Notes: Calculation 1: 27,594,179*13.9%=3,835,591 (the rest is the same). Calculation 2: 3,835,591 *93.99%*14.4%=519,130 (the rest is the same). Calculation 3: For Condrosan®/Condrosulf®/CS Kern: (2,993,624 units*60 capsules per unit)/(2 capsules/day of Condrosan® [800 mg/day]*180 days of treatment according to their summary of product characteristics)*21.2% (MPR)= 105,775 patients (Condrosan, 201933). Same for Droglican (Droglican, 201934). *MPR (medication possession ratio) ≥ 50% (regular use of the drug). **An annual increase in sales of 2% is expected.
Abbreviation: CS, chondroitin sulfate with or without glucosamine.`